[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377830-105":59,"doc-detail-377830-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","t-cell-immunotherapy-for-cervical-cancer-challenges-and-opportunities","T cell immunotherapy for cervical cancer - challenges and opportunities","","T cell immunotherapy has shown meaningful therapeutic effects in clinical practice, offering new hope for cervical cancer treatment. CD8+ T cells function as key cytotoxic effector cells in antitumor immunity, making T cell–based immunotherapy central to cellular immunotherapy strategies. Both tumor-infiltrating lymphocytes (TIL) and engineered T cell approaches have progressed, including in vitro expansion and re-infusion of antigen-binding T cells such as CAR-T, TCR-T. This review compiles preclinical research and clinical applications while addressing major challenges.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/t-cell-immunotherapy-for-cervical-cancer-challenges-and-opportunities/377830/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/t-cell-immunotherapy-for-cervical-cancer-challenges-and-opportunities/377830.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role do CD8+ T cells play in cervical cancer immunotherapy?","Question",{"text":113,"@type":114},"CD8+ T cells act as effective cytotoxic effector cells in antitumor immunity, supporting the foundation of T cell–based immunotherapy for cervical cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which T-cell immunotherapy approaches are discussed for cervical cancer?",{"text":118,"@type":114},"The text highlights tumor-infiltrating lymphocytes (TIL) and engineered T cell therapies, including CAR-T and TCR-T strategies expanded in vitro and re-infused to target tumor cells.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is HPV considered critical in the development of cervical cancer?",{"text":122,"@type":114},"The document states that persistent cervical HPV infection is a critical condition, while also noting that HPV infection alone cannot fully explain all abnormal changes in cervical epithelium.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},377830,1790293760,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 26 April 2023  \nDOI 10.3389/fimmu.2023.1105265  \nOPEN ACCESS  \nEDITED BY Ning Wei,  \nAlbert Einstein College of Medicine, United States  \nREVIEWED BY Xiaotao Jiang,  \nSouthern Medical University, China Zhu Zhang,  \nHong Kong Baptist University, Hong Kong SAR, China  \n*CORRESPONDENCE Jie Min  \n [691055202@qq.com](691055202@qq.com)  \n†These authors have contributed equally to this work and share first authorship  \nSPECIALTY SECTION  \nThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology  \nRECEIVED 22 November 2022  \nACCEPTED 27 February 2023  \nPUBLISHED 26 April 2023  \nCITATION  \nYu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-hui L, Zou H and Min J (2023) T cell  \nimmunotherapy for cervical cancer: challenges and opportunities.  \nFront. Immunol. 14:1105265 .  \ndoi: 10.3389/fimmu.2023.1105265  \nCOPYRIGHT  \n© 2023 Yu, Lanqing, Huang, Xin, Minglin, Fa-hui, Zou and Min. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nT cell immunotherapy for cervical cancer: challengesand opportunities  \nLingfeng Yu 1†, Gong Lanqing 2†, Ziyu Huang 3†, Xiaoyan Xin 3, Liang Minglin 3, Lv Fa-hui 4, Hongmei Zou 5 and Jie Min 2*  \n1School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China, 2 Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3School of Arts and Sciences, Brandeis University, Boston, MA, United States, 4 Department of Obstetrics and Gynecology, The Second People’s Hospital of Hefei, Hefei, Anhui, China, 5 Department of Obstetrics, Qianjiang Central Hospital, Qianjiang, Hubei, China  \nCancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded in vitro, and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.  \nKEYWORDS  \ncervical cancer, engineered T cells, TILs, TCR-Ts, CAR-Ts, immune checkpoint  \n1 Introduction  \nCervical cancer is a disease in which malignant tumor cells are formed in the female cervix, and it is the most common malignant tumor in the female reproductive system. It occurs more commonly in women aged 40 to 60 years old than female of younger age groups.  \nAt present, research on cervical cancer cannot fully explain the pathogenesis of cervical cancer yet, however, the evidence shows the onset of cervical cancer may be related to a series of factors such as early marriage, multiple births, cervical lacerations, poor local hygiene, and smegma irritation. Since the nineties, research has further confirmed that human papillomavirus (HPV) plays a significant role in the pathogenesis of cervical cancer (1) .  \nIt is found that almost all (99%) cases of cervical cancer, patients have persistent cervical HPV infection (2) . There are more than 1,00 subtypes of HPV virus; among all, 40 subtypes are associated with reproductive tract diseases and 10 high-r","cbCaiokmc29Svu41","https://ap.wps.com/l/cbCaiokmc29Svu41","pdf",583301,12,"English","# Introduction\n## Cervical cancer epidemiology and risk factors\n## HPV infection and mechanisms\n## Current treatment landscape and rationale for T-cell immunotherapy","[{\"question\":\"What role do CD8+ T cells play in cervical cancer immunotherapy?\",\"answer\":\"CD8+ T cells act as effective cytotoxic effector cells in antitumor immunity, supporting the foundation of T cell–based immunotherapy for cervical cancer.\"},{\"question\":\"Which T-cell immunotherapy approaches are discussed for cervical cancer?\",\"answer\":\"The text highlights tumor-infiltrating lymphocytes (TIL) and engineered T cell therapies, including CAR-T and TCR-T strategies expanded in vitro and re-infused to target tumor cells.\"},{\"question\":\"Why is HPV considered critical in the development of cervical cancer?\",\"answer\":\"The document states that persistent cervical HPV infection is a critical condition, while also noting that HPV infection alone cannot fully explain all abnormal changes in cervical epithelium.\"}]","T cell immunotherapy for cervical cancer - challenges and opportunities | PDF",1790227312]